Radiation Oncology

Data from the phase 2 RECLAIM trial demonstrate the feasibility of a multimodal strategy in a patient population with limited therapeutic options.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

Results from cohort C of the TRASTS study showed trabectedin/radiotherapy had positive response rates for patients with resectable retroperitoneal L-sarcomas.

The hypofractionated radiotherapy schedule was noninferior to the standard fractionation schedule regarding HRQOL for patients with cervical cancer.

Efficacy with carboplatin-based induction-concurrent chemotherapy was noninferior to cisplatin, representing a viable alternative for patients with LA-NPC.

Patients with breast cancer and macrometastases who omitted axillary lymph node dissection experienced noninferior survival compared with those who didn’t.

Disease control was observed in all patients who received JNJ-1900 in part 1 of the phase 2 CONVERGE trial.

Philip Blumenfeld, MD, discussed the feasibility of radium 224 Alpha DaRT sources delivered via endoscopic ultrasound for patients with pancreatic cancer.

Patients with breast cancer who omitted sentinel lymph node surgery did not have an increased uptake in other forms of treatment like radiation therapy.

Heath Skinner, MD, PhD, discussed current standards for radiotherapy in head and neck cancers and highlighted multidisciplinary collaboration within UPMC.

According to the phase 3 TORPEdO investigators, where IMPT is not used routinely for OPSCC, IMRT remains the standard of care.

Most treatment-related adverse effects were grades 1 or 2, and no grade 4 adverse effects or treatment-related deaths were observed with Lu-PSMA-617.

Mina Fam, MD, explored the integration of multiparametric MRI and genomics in focal HIFU selection and compared its AE profile to radical intervention.

Poster presentations at ELCC 2026 highlighted potential advances in neoadjuvant immunotherapy, intratumoral radioenhancers, and other modalities.

Low-grade toxicity related to durvalumab in the ASTEROID trial was common, which mostly consisted of skin reactions, pruritus, and fatigue.

The future of radiation oncology will be largely affected by artificial intelligence and genomics, according to Sheila D. Rege, MD, FACRO.

Bridget Koontz, MD, discussed evaluating the role of concurrent hormone therapy and brachytherapy for prostate cancer that she presented at ASCO GU.

Tousimis explored the feasibility, complications, and surgical strategies for nipple-sparing mastectomy in patients with a history of radiation therapy.

SkinCure Oncology filed a federal lawsuit against CMS and HHS to challenge the elimination of reimbursement for image-guided radiation therapy for nonmelanoma skin cancer.

A total of 46.6% of patients showed a favorable response to ultrahypofractionation radiotherapy for locally advanced breast cancer.

Jason Molitoris, MD, PhD, discussed 2025 data on proton therapy for oropharyngeal cancer, highlighting immune preservation and reduced long-term AEs.

Charlotte Ivey Rivers, MD, discussed the importance of rare CNS tumor research, upcoming trial data in meningioma, and the role of functional radiosurgery.

Fumiko Chino, MD, discussed the nuances of patient-centered care, addressing financial toxicity, AI bias in oncology, and survivorship.